argenx SE
XBRU:ARGX
Intrinsic Value
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. [ Read More ]
The intrinsic value of one ARGX stock under the Base Case scenario is 465.49 EUR. Compared to the current market price of 366.6 EUR, argenx SE is Undervalued by 21%.
Valuation Backtest
argenx SE
Run backtest to discover the historical profit from buying and selling ARGX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
argenx SE
Current Assets | 4.1B |
Cash & Short-Term Investments | 3.2B |
Receivables | 499.3m |
Other Current Assets | 444.6m |
Non-Current Assets | 418.7m |
Long-Term Investments | 47.2m |
PP&E | 22.7m |
Intangibles | 125.2m |
Other Non-Current Assets | 223.7m |
Current Liabilities | 423m |
Accounts Payable | 245.6m |
Accrued Liabilities | 150.9m |
Other Current Liabilities | 26.5m |
Non-Current Liabilities | 22m |
Long-Term Debt | 15.4m |
Other Non-Current Liabilities | 6.6m |
Earnings Waterfall
argenx SE
Revenue
|
1.2B
USD
|
Cost of Revenue
|
-117.8m
USD
|
Gross Profit
|
1.1B
USD
|
Operating Expenses
|
-1.5B
USD
|
Operating Income
|
-420.6m
USD
|
Other Expenses
|
125.6m
USD
|
Net Income
|
-295.1m
USD
|
Free Cash Flow Analysis
argenx SE
ARGX Profitability Score
Profitability Due Diligence
argenx SE's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
argenx SE's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
ARGX Solvency Score
Solvency Due Diligence
argenx SE's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
argenx SE's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARGX Price Targets Summary
argenx SE
According to Wall Street analysts, the average 1-year price target for ARGX is 458.48 EUR with a low forecast of 166.65 EUR and a high forecast of 630 EUR.
Shareholder Return
ARGX Price
argenx SE
Average Annual Return | 34.48% |
Standard Deviation of Annual Returns | 24.69% |
Max Drawdown | -39% |
Market Capitalization | 21.7B EUR |
Shares Outstanding | 59 118 800 |
Percentage of Shares Shorted |
N/A
|
ARGX News
Last Important Events
argenx SE
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
argenx SE
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. The company is headquartered in Breda, Noord-Brabant and currently employs 650 full-time employees. The company went IPO on 2014-07-10. The company creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one ARGX stock under the Base Case scenario is 465.49 EUR.
Compared to the current market price of 366.6 EUR, argenx SE is Undervalued by 21%.